{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T18:26:51Z","timestamp":1786991211565,"version":"build-2736575974"},"reference-count":24,"publisher":"Public Library of Science (PLoS)","issue":"8","license":[{"start":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T00:00:00Z","timestamp":1786924800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS One"],"abstract":"<jats:sec id=\"sec001\">\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Thyroglobulin (Tg) level is one of the well-known factors affecting the outcome of radioactive iodine treatment in differentiated thyroid cancer, though this tumor marker is affected by the thyroid-stimulating hormone (TSH) level. To negate this influence, there is an effort to use the stimulated thyroglobulin\/ thyroid-stimulating hormone (sTg\/TSH) ratio instead of stimulated thyroglobulin (sTg) level alone. N1b cervical lymph node metastasis is also another factor mentioned in literature. This study aims to demonstrate the significance of these two factors whether they affect the treatment outcome in differentiated thyroid cancer patients who received the first radioactive iodine treatment.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"sec002\">\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>This was a retrospective analytical observational study. The population were patients with differentiated thyroid cancer with an age of 18 years and above who received the first radioactive iodine treatment at our center from 1 January 2020\u201331 December 2023. The total population was 227 patients. Logistic regression analysis was done to determine the significant factors affecting the outcome of the first radioactive iodine treatment.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"sec003\">\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>In 227 patients, the median value for sTg and sTg\/TSH ratio were 9.4 ng\/mL and 0.2, respectively. Multiple logistic regression found that sTg\/TSH ratio and N1b status were not independent risk factors for non-excellent response after radioactive iodine treatment. The independent risk factors were male sex, intermediate and high risk of recurrence, stage II and sTg of more than or equal to 9.4 ng\/mL. Receiver operating characteristic (ROC) analysis showed that sTg and sTg\/TSH ratio had rather similar performance in differentiating between excellent and non-excellent response groups.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"sec004\">\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>sTg\/TSH ratio and N1b cervical lymph node metastasis were not significant independent factors for non-excellent response after the first radioactive iodine treatment, which was possibly due to multicollinearity and small sample size. Independent risk factors for non-excellent response of the first radioiodine treatment were male sex, intermediate and high risk of recurrence, stage II and sTg of more than or equal to 9.4 ng\/mL.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1371\/journal.pone.0349850","type":"journal-article","created":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T17:32:21Z","timestamp":1786987941000},"page":"e0349850","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":0,"title":["The effects of stimulated thyroglobulin\/ thyroid-stimulating hormone ratio and N1b status on the efficacy of the first I-131 treatment in patients with differentiated thyroid cancer"],"prefix":"10.1371","volume":"21","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4162-0914","authenticated-orcid":true,"given":"Supanida","family":"Mayurasakorn","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charoonsak","family":"Somboonporn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1338-511X","authenticated-orcid":true,"given":"Daris","family":"Theerakulpisut","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"340","published-online":{"date-parts":[[2026,8,17]]},"reference":[{"issue":"3","key":"pone.0349850.ref001","first-page":"209","article-title":"Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"71","author":"H Sung","year":"2021","journal-title":"CA Cancer J Clin"},{"issue":"4","key":"pone.0349850.ref002","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1016\/S2213-8587(21)00049-8","article-title":"A worldwide journey of thyroid cancer incidence centred on tumour histology","volume":"9","author":"ED Rossi","year":"2021","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"7","key":"pone.0349850.ref003","doi-asserted-by":"crossref","first-page":"1284","DOI":"10.1158\/1055-9965.EPI-21-1440","article-title":"Epidemiology of Thyroid Cancer","volume":"31","author":"CM Kitahara","year":"2022","journal-title":"Cancer Epidemiology, Biomarkers & Prevention"},{"issue":"1","key":"pone.0349850.ref004","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1089\/thy.2015.0020","article-title":"2015 American Thyroid Association Management Guidelines for Adult Patients with Thyroid Nodules and Differentiated Thyroid Cancer: The American Thyroid Association Guidelines Task Force on Thyroid Nodules and Differentiated Thyroid Cancer","volume":"26","author":"BR Haugen","year":"2016","journal-title":"Thyroid"},{"issue":"12","key":"pone.0349850.ref005","doi-asserted-by":"crossref","first-page":"1102","DOI":"10.1097\/RLU.0b013e3182291c65","article-title":"Predictive value of preablation stimulated thyroglobulin and thyroglobulin\/thyroid-stimulating hormone ratio in differentiated thyroid cancer","volume":"36","author":"Y Lin","year":"2011","journal-title":"Clin Nucl Med"},{"issue":"1","key":"pone.0349850.ref006","doi-asserted-by":"crossref","first-page":"42","DOI":"10.3109\/07435800.2016.1173056","article-title":"Thyroglobulin levels and thyroglobulin\/thyrotropin ratio could predict the success of the ablative\/therapeutic 131I in the differentiated thyroid cancers","volume":"42","author":"PGC Trevizam","year":"2017","journal-title":"Endocr Res"},{"issue":"1","key":"pone.0349850.ref007","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1002\/hed.24550","article-title":"Prediction of radioactive iodine remnant ablation failure in patients with differentiated thyroid cancer: A cohort study of 740 patients","volume":"39","author":"M Prpic","year":"2017","journal-title":"Head Neck"},{"issue":"4","key":"pone.0349850.ref008","first-page":"428","article-title":"Thyroglobulin\/thyrotropin ratio for predicting long-term response in differentiated thyroid carcinoma: a retrospective study","volume":"65","author":"Junior De Marchi AF","year":"2021","journal-title":"Arch Endocrinol Metab"},{"issue":"1","key":"pone.0349850.ref009","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1186\/s12902-022-01261-7","article-title":"Comparing the efficacy of thyroglobulin and thyroglobulin\/ thyroid-stimulating hormone ratio models in predicting a successful response to radioactive iodine therapy","volume":"23","author":"Y Ju","year":"2023","journal-title":"BMC Endocr Disord"},{"key":"pone.0349850.ref010","doi-asserted-by":"crossref","first-page":"610273","DOI":"10.1155\/2014\/610273","article-title":"Preablation Stimulated Thyroglobulin\/TSH Ratio as a Predictor of Successful I(131)Remnant Ablation in Patients with Differentiated Thyroid Cancer following Total Thyroidectomy","volume":"2014","author":"S Zubair Hussain","year":"2014","journal-title":"J Thyroid Res"},{"key":"pone.0349850.ref011","doi-asserted-by":"crossref","first-page":"640","DOI":"10.3389\/fonc.2018.00640","article-title":"Efficacy and affecting factors of 131I thyroid remnant ablation after surgical treatment of differentiated thyroid carcinoma","volume":"8","author":"C Wang","year":"2018","journal-title":"Front Oncol"},{"issue":"3","key":"pone.0349850.ref012","doi-asserted-by":"crossref","first-page":"989","DOI":"10.1007\/s12020-023-03625-y","article-title":"A novel nomogram integrated with preablation stimulated thyroglobulin and thyroglobulin\/thyroid-stimulating hormone ratio to predict the therapeutic response of intermediate\u2011 and high\u2011risk differentiated thyroid cancer patients: a bi-center retrospective study","volume":"84","author":"R Wen","year":"2024","journal-title":"Endocrine"},{"key":"pone.0349850.ref013","doi-asserted-by":"crossref","first-page":"601960","DOI":"10.3389\/fendo.2021.601960","article-title":"The Influences of TSH Stimulation Level, Stimulated Tg Level and Tg\/TSH Ratio on the Therapeutic Effect of 131I Treatment in DTC Patients","volume":"12","author":"W Zheng","year":"2021","journal-title":"Front Endocrinol (Lausanne)"},{"issue":"1","key":"pone.0349850.ref014","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1007\/s12149-016-1133-4","article-title":"Low- and high-dose radioiodine therapy for low-\/intermediate-risk differentiated thyroid cancer: a preliminary clinical trial","volume":"31","author":"Y Qu","year":"2017","journal-title":"Ann Nucl Med"},{"key":"pone.0349850.ref015","doi-asserted-by":"crossref","first-page":"34915","DOI":"10.1038\/srep34915","article-title":"Multiple-factor analysis of the first radioactive iodine therapy in post-operative patients with differentiated thyroid cancer for achieving a disease-free status","volume":"6","author":"N Liu","year":"2016","journal-title":"Sci Rep"},{"issue":"12","key":"pone.0349850.ref016","doi-asserted-by":"crossref","DOI":"10.1007\/s40618-017-0714-y","article-title":"Latero-cervical lymph node metastases (N1b) represent an additional risk factor for papillary thyroid cancer outcome","volume":"40","author":"G Sapuppo","year":"2017","journal-title":"J Endocrinol Invest"},{"issue":"6","key":"pone.0349850.ref017","doi-asserted-by":"crossref","first-page":"584","DOI":"10.1590\/2359-3997000000307","article-title":"Metastatic lymph node characteristics as predictors of recurrence\/persistence in the neck and distant metastases in differentiated thyroid cancer","volume":"61","author":"MP Barbosa","year":"2017","journal-title":"Arch Endocrinol Metab"},{"issue":"12","key":"pone.0349850.ref018","doi-asserted-by":"crossref","first-page":"1286","DOI":"10.4158\/EP-2019-0155","article-title":"Unfavorable responses to radioiodine therapy in n1b papillary thyroid cancer: a propensity score matching study","volume":"25","author":"Y-Q Liu","year":"2019","journal-title":"Endocr Pract"},{"issue":"4","key":"pone.0349850.ref019","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1089\/thy.2017.0473","article-title":"Prognostic Implication of N1b Classification in the Eighth Edition of the Tumor-Node-Metastasis Staging System of Differentiated Thyroid Cancer","volume":"28","author":"M Kim","year":"2018","journal-title":"Thyroid"},{"issue":"1","key":"pone.0349850.ref020","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1007\/s40618-015-0319-2","article-title":"Predictors of incomplete response to therapy among Filipino patients with papillary thyroid cancer in a tertiary hospital","volume":"39","author":"ES Mendoza","year":"2016","journal-title":"J Endocrinol Invest"},{"issue":"1","key":"pone.0349850.ref021","doi-asserted-by":"crossref","DOI":"10.1210\/jendso\/bvaa178","article-title":"Course and predictive factors of incomplete response to therapy in low- and intermediate-risk thyroid cancer","volume":"5","author":"AS Alzahrani","year":"2020","journal-title":"J Endocr Soc"},{"issue":"2","key":"pone.0349850.ref022","doi-asserted-by":"crossref","first-page":"737","DOI":"10.7314\/APJCP.2015.16.2.737","article-title":"Factors affecting disease-free status of differentiated thyroid carcinoma patients","volume":"16","author":"K Thamnirat","year":"2015","journal-title":"Asian Pac J Cancer Prev"},{"issue":"10","key":"pone.0349850.ref023","doi-asserted-by":"crossref","first-page":"1106","DOI":"10.1089\/thy.2015.0104","article-title":"Survival from Differentiated Thyroid Cancer: What Has Age Got to Do with It?","volume":"25","author":"I Ganly","year":"2015","journal-title":"Thyroid"},{"issue":"8","key":"pone.0349850.ref024","doi-asserted-by":"crossref","first-page":"2754","DOI":"10.1210\/jc.2012-1533","article-title":"The utility of serum thyroglobulin measurement at the time of remnant ablation for predicting disease-free status in patients with differentiated thyroid cancer: a meta-analysis involving 3947 patients","volume":"97","author":"RC Webb","year":"2012","journal-title":"J Clin Endocrinol Metab"}],"container-title":["PLOS One"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0349850","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T17:32:26Z","timestamp":1786987946000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0349850"}},"subtitle":[],"editor":[{"given":"Antimo","family":"Migliaccio","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2026,8,17]]},"references-count":24,"journal-issue":{"issue":"8","published-online":{"date-parts":[[2026,8,17]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0349850","relation":{},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,17]]}}}